echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JAMA NEUROLOGY: ARB DRUGS NOT ONLY REDUCE HYPERTENSIVE DISORDERS, BUT ALSO SIGNIFICANTLY REDUCE THE INCIDENCE OF EPILEPSY

    JAMA NEUROLOGY: ARB DRUGS NOT ONLY REDUCE HYPERTENSIVE DISORDERS, BUT ALSO SIGNIFICANTLY REDUCE THE INCIDENCE OF EPILEPSY

    • Last Update: 2022-10-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Arterial hypertension is associated
    with an increased incidence of epilepsy.
    The results of animal studies suggest that angiotensin receptor blocker (ARB) treatment can suppress seizures
    .
    However, there is a lack of clinical data to support the use
    of ARB therapy in humans.
    The aim of the study was to assess whether ARB treatment was associated
    with a decrease in the incidence of epilepsy in people with hypertension.

    This cohort study obtained data
    from the Disease Analyzer Database (IQVIA) in hypertensive patients aged 18 years or older and at least one prescription for antihypertensive drugs.
    Between January 2010 and December 2020, patients were treated
    in 1,274 general clinics in Germany.
    There are data
    on 1553875 patients who have been prescribed at least 1 antihypertensive drug.
    Patients treated with class 1 of the four antihypertensive drugs (β-blockers BBB, ARBs, ACE, ACE, and calcium-channel blockers [CCBs]) were matched
    using propensity scores.
    The primary outcome was the incidence of
    epilepsy associated with ARB treatment compared to other antihypertensive drug classes.

    Results A total of 168612 patients were included in the propensity score match, with 42,153 patients in each antihypertensive drug class
    .
    The mean age of patients [SD] was 62.
    3 [13.
    5] years, and 21 667 (51.
    4%) were women
    .
    The incidence of epilepsy within 5 years was lowest in patients receiving ARB therapy (0.
    27% at 1 year, 0.
    63% at 3 years, 0.
    99% at 5 years) and highest in patients receiving BBB and CCB (0.
    38% at 1 year
    - both β-blockers and CCB); At 3 years, β-blockers were 0.
    91% and CCB 0.
    93%; β-blockers are 1.
    47%; CCB was 1.
    48% at 5 years).

    Treatment with ARBs was associated with a significant 23% reduction in epilepsy incidence compared to other drug classes (HR = 0.
    77; 95% CI, 0.
    65 to 0.
    90).

    In this cohort study of hypertensive patients, ARB treatment was associated
    with a significantly lower incidence of epilepsy.
    The findings suggest that antihypertensive drugs can be used as a new way to
    prevent epilepsy in patients with arterial hypertension.

    References:

    Association Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension.
    JAMA Neurol.
    Published online October 17, 2022.
    doi:10.
    1001/jamaneurol.
    2022.
    3413

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.